
Improving patient prognostication in mantle cell lymphoma informs treatment decisions and enhances our understanding of the disease's biology.
Anita Kumar, MD, is an associate attending physician and lymphoma specialist at Memorial Sloan Kettering Cancer Center in New York, NY.

Improving patient prognostication in mantle cell lymphoma informs treatment decisions and enhances our understanding of the disease's biology.

Anita Kumar, MD, discusses findings from the phase 2 study of zanubrutinib, obinutuzumab, and venetoclax in TP53-mutant mantle cell lymphoma presented at ASH 2023.

Published: December 20th 2023 | Updated: